Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma

BACKGROUND: It is well known that renal cell carcinoma (RCC) represents one of the most immune-responsive cancers. Although the lack of defined antigens in RCC has hindered more specific vaccine development, research regarding vaccination therapy has been of special interest for the treatment of RCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, K, Minami, T, Nozawa, M, Uemura, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619266/
https://www.ncbi.nlm.nih.gov/pubmed/23470466
http://dx.doi.org/10.1038/bjc.2013.90

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619266/
https://www.ncbi.nlm.nih.gov/pubmed/23470466
http://dx.doi.org/10.1038/bjc.2013.90

Ejemplares similares